Table 2.

Study characteristics.

Study	Depression severity	N	Female (%)	Setting	N session	CBM methods	Measures	Control condition
Woolridge et al. (2022)	Moderate	40	65	Lab	3	CBM-A	BDI-II1	Placebo
Yang et al. (2015)	Mild	54	68.5	Lab	8	CBM-A	BDI-II	placebo
Baert et al. (2010)	Mild	18	88.8	Home	10	CBM-A	BDI-II	No training
Chen et al. (2022)	Moderate	40	95	Lab	4	CBM-I	SDS2	No training
Basanovic et al. (2019)	Mild	114	48.5	Home	20	CBM-I & CBM-A	PHQ-93	Placebo
Lang et al. (2012)	Moderate	26	73	Home	7	i-CBMI	BDI-II	Placebo
Nejati et al. (2018)	Moderate	22	63.6	Lab	10	CBM-I	BDI-II	Placebo
Torkan et al. (2014)	Severe	26	57.6	Home	7	i-CBMI	BDI-II	No training
Krejtz et al. (2018)	Moderate	60	56.7	Home	14	CBM-A	CES-D4	Placebo
Pictet et al. (2016)	Moderate	67	76	Home	4	i-CBMI	BDI-II	No training
Study	Country		Mean age	IG depression score		CG depression score	Specific control condition
Woolridge et al. (2022)	Canada		44.5 ± 14.5	17.79 ± 12.2		23.45 ± 11.89	Neutral stimuli
Yang et al. (2015)	China		19.5 ± 1.3	10.96 ± 4.62		16.78 ± 5.09	Neutral (50%)
							Sad (50%)
Baert et al. (2010)	Belgium		19.4*	11 ± 6.19		13 ± 5.64	Invalid (50%)
							Valid (50%)
Chen et al. (2022)	China		21.3 ± 2.2	50.75 ± 8.07		60.63 ± 6.9	Waiting list
Basanovic et al. (2019)	Australia		60.2 ± 9.7	7.2 ± 3.67		7.24 ± 4.07	Random stimuli
Lang et al. (2012)	England		28.5 ± 9.2	19 ± 10.73		25.92 ± 9.66	Positive (50%)
							Negative (50%)
Nejati et al. (2018)	Iran		19.9 ± 1.2	7.72 ± 6.05		23.27 ± 9.93	Negative (50%)
							Ambiguous (50%)
Torkan et al. (2014)	Iran		28.5 ± 9.7	21.15 ± 10.11		26.92 ± 11.49	No training
Krejtz et al. (2018)	Poland		35.1 ± 13.0	25.67 ± 10.4		30.11 ± 11.25	Positive (50%)
							Neutral (50%)
Pictet et al. (2016)	Sweden		26.3 ± 8.9	18.66 ± 9.84		22.76 ± 10.34	Waiting list

¹Beck Depression Inventory; ²The Self Directed Search Questionnaire; ³Patient Health Questionnaire-9; and ⁴Center for Epidemiologic Studies Depression Scale. ^*None SD data; IG: Intervention group; CG: control group.